Transgene SA

OTCPK:TRGN.F Stock Report

Market Cap: US$234.6m

Transgene Management

Management criteria checks 2/4

Transgene's CEO is Alessandro Riva, appointed in Jun 2023, has a tenure of 3.08 years. directly owns 0.034% of the company’s shares, worth $79.73K. The average tenure of the management team and the board of directors is 2 years and 3.3 years respectively.

Key information

Alessandro Riva

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.1yrs
CEO ownership0.03%
Management average tenure2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Alessandro Riva's remuneration changed compared to Transgene's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-€38m

Sep 30 2025n/an/a

-€37m

Jun 30 2025n/an/a

-€37m

Mar 31 2025n/an/a

-€35m

Dec 31 2024€840k€600k

-€34m

Sep 30 2024n/an/a

-€28m

Jun 30 2024n/an/a

-€23m

Mar 31 2024n/an/a

-€23m

Dec 31 2023€510k€350k

-€22m

Sep 30 2023n/an/a

-€28m

Jun 30 2023n/an/a

-€33m

Mar 31 2023n/an/a

-€33m

Dec 31 2022€304kn/a

-€33m

Compensation vs Market: Insufficient data to establish whether Alessandro's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.

CEO

Alessandro Riva (66 yo)

3.1yrs
Tenure
€840,000
Compensation

Dr. Alessandro Riva, M.D., serves as an Independent Director at Bicycle Therapeutics plc since March 25, 2025. He serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Alessandro Riva
CEO & Chairman of the Board3.1yrs€840.00k0.034%
$ 79.7k
Lucie Larguier
VP & Chief Financial Officer2.3yrsno datano data
Simone Steiner
Chief Technical Officer1.3yrsno datano data
Maurizio Ceppi
Chief Scientific Officer1.8yrsno datano data
John Felitti
VP, General Counsel & Corporate Secretary10.3yrsno datano data
Christelle Schwoerer
Chief Human Resources Officer2.3yrsno datano data
James Wentworth
VP & Chief Business Officer2.5yrsno datano data
Emmanuelle Dochy
VP of Medical Affairs & Chief Medical Officer1.8yrsno datano data
Katell Huang
Head of Translational Medicineno datano datano data
Feriel Marin
Interim Chief Quality Officerless than a yearno datano data
Sandrine Lemius
Interim Deputy CEO of Responsible Pharmacistless than a yearno datano data
Gaelle Stadtler
VP & Director of Human Resourcesno datano datano data
2.0yrs
Average Tenure
50yo
Average Age

Experienced Management: TRGN.F's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alessandro Riva
CEO & Chairman of the Board4.2yrs€840.00k0.034%
$ 79.7k
Benoit Habert
Director26.5yrs€26.00k0.038%
$ 88.2k
Jean-Luc Belingard
Non-Independent Director13.1yrsno datano data
Jean-Yves Blay
Independent Director4.2yrs€24.00kno data
John Bell
Member of Scientific Advisory Board3.3yrsno datano data
Emmanuelle Quiles
Independent Director1yrno datano data
Pedro Romero
Member of Scientific Advisory Boardno datano datano data
Ignacio Melero Bermejo
Scientific Advisorless than a yearno datano data
Carol Stuckley
Independent Director3.2yrs€45.00kno data
Sandrine Flory
Director5.5yrsno datano data
Antoine Italiano
Scientific Advisorless than a yearno datano data
Michel de Puchesse
Director2.2yrsno data0.00016%
$ 375.4
3.3yrs
Average Tenure
64yo
Average Age

Experienced Board: TRGN.F's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 16:25
End of Day Share Price 2026/04/28 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Transgene SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arsene GuekamCIC Market Solutions (ESN)
Michael Thomas CooperEdison Investment Research
Martial DescouturesODDO BHF Corporate & Markets